Latest News about ESALY

Recent news which mentions ESALY

< Previous 1 2 3 4 5 Next >

Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote

June 12, 2023

Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low

June 12, 2023

Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'

June 08, 2023

Amazon Considers Launching Ad-Supported Prime Video Tier, Google & Microsoft Face Backlash For Ad Inclusion In AI Trials, Airbus Records One-Third Jump In May Deliveries: Today's Top Stories

June 08, 2023

FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval

June 08, 2023

Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades'

June 01, 2023

After Back To Back Failure For Keytruda Plus Lenvima, Merck Touts Durable Clinical Benefit For The Combo In Advanced Kidney Cancer

May 26, 2023

Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen

May 04, 2023

Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!

April 21, 2023

Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer

April 10, 2023

Tesla Manufactured 4,000 Model Ys In One Week, UBS Prepping For Massive Layoffs, McDonald's Temporary Shuttering Of US Offices: Today's Top Stories

April 03, 2023

National Institute on Aging Aims Building $300M Alzheimer's Research Database

April 03, 2023

Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug

March 31, 2023

7 Healthcare Stocks to Buy for Long-Term Growth and Stability

March 21, 2023

Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments

March 16, 2023

Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity

March 14, 2023

Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment

March 06, 2023

Why Anavex Life Sciences Stock Bolted Higher in January

February 08, 2023

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More

January 31, 2023

Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?

January 25, 2023

Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval

January 19, 2023

This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich

January 17, 2023

Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?

January 10, 2023

Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill

January 07, 2023

FDA approves treatment for people with mild forms of Alzheimer’s

January 06, 2023

FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway

January 06, 2023

Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?

January 06, 2023

1 Stock Defying the Downturn to Buy, and 1 to Avoid

January 06, 2023

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors

December 27, 2022

1 Green Flag and 1 Red Flag for Biogen

December 23, 2022

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.